Kiniksa Pharmaceuticals International, plc (KNSA) Stock: Price, Metrics & AI Assessment

COMPANY DATA

Sector: HealthcareIndustry: Medical - PharmaceuticalsCountry: GBCEO: Sanj K. PatelEmployees: 366Market cap: 6 BIPO: 24/05/2018Web: www.kiniksa.com

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic…

PRICE HISTORY

26/08/25+136.1 %26/08/26

1D

-1.2 %

1W

-1.9 %

1M

+24.7 %

6M

+85.4 %

YTD

+92.2 %

1Y

+136.1 %

2Y

+187.7 %

5Y

+519.7 %

10Y

–

EARNINGS

Next earnings date

27/10/2026 (in 62 days)

Volatility around earnings

~63% stronger price swings than usual

SCORES

Valuation

Valued significantly more expensively than its own historical average.

Why this value? Details with Pro only.

Trend

Very strong uptrend.

Why this value? Details with Pro only.

Quality

Average balance sheet quality.

Why this value? Details with Pro only.

Dividend

Not enough data yet for an assessment.

Growth

Very strong expected growth at a fair price.

Why this value? Details with Pro only.

Insider

Insiders are selling more shares than they buy.

Why this value? Details with Pro only.

Earnings

Roughly meets expectations.

Why this value? Details with Pro only.

Revisions

Not enough data yet for an assessment.

Sentiment

Not enough data yet for an assessment.

Short Pressure

Persistently high short volume ratio, partly with a Reg SHO threshold listing.

Why this value? Details with Pro only.

Register for free

Unlock all 9 scores

4 credits free on registration
Access to virtual portfolios and watchlist
No credit card, no payment details needed
No subscription, no minimum term
Our own servers in Germany, no US cloud

Create account →

Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 26/08/2026.

ASK THE AGENTS ABOUT KNSA

ANALYST ASSESSMENT

PRICE TARGET LOW

US$71.00

CONSENSUS

US$86.40

MEDIAN

US$90.00

PRICE TARGET HIGH

US$99.00

0

STRONG BUY

11

BUY

0

HOLD

0

SELL

0

STRONG SELL

11

TOTAL · Buy

DATE	ANALYST FIRM	RATING	ACTION
30/07/2026	Goldman Sachs	Buy	maintain
29/07/2026	Wedbush	Outperform	maintain
29/07/2026	Citigroup	Buy	maintain
29/07/2026	JP Morgan	Overweight	maintain
29/07/2026	Canaccord Genuity	Buy	maintain
23/07/2026	Goldman Sachs	Buy	maintain
13/07/2026	Wells Fargo	Overweight	maintain
29/06/2026	Wedbush	Outperform	maintain

METRICS

P/E

74.08

P/B

9.4

EV/EBITDA

52.4

RETURN ON EQUITY

3.9 %

NET MARGIN

10.4 %

DEBT/EQUITY

0.01

DIVIDEND YIELD

0 %

AS OF

30/06/2026

FREE FLOAT & LIQUIDITY

FREE FLOAT

95.6 %

FLOAT SHARES

72,858,556

AVG. DAILY VOLUME (30D)

612,275

INSIDER TRANSACTIONS (SEC)

DATE	INSIDER	ROLE	TRANSACTION	SHARES	PRICE	PLAN TYPE
21/08/2026	Quart Barry D	Director	Gift	2,600	0	Spontaneous
04/08/2026	Levy Richard S	Director	Option exercise	403	–	Spontaneous
31/07/2026	Cole G Bradley	Director	Gift	4,500	0	Spontaneous
31/07/2026	Cole G Bradley	Director	Sale	3,673	81.43	Spontaneous
02/06/2026	Quart Barry D	Director	Option exercise	2,799	–	Spontaneous

Page 1 / 6

INSTITUTIONAL HOLDERS

FUND / INSTITUTION	SHARES	CHANGE	AS OF
FMR LLC	6,971,361	+147,661	30/06/2026
Rubric Capital Management LP	3,999,800	+249,800	30/06/2026
BAKER BROS. ADVISORS LP	2,834,643	+8,397	30/06/2026
BlackRock, Inc.	2,739,615	+2,252,878	30/06/2026
TANG CAPITAL MANAGEMENT LLC	2,259,889	+0	30/06/2026

Page 1 / 3